Palisade Bio Participates in Virtual Investor “What This Means” Segment

Core Viewpoint - Palisade Bio announced positive preclinical data for its lead product candidate, PALI-2108, aimed at treating Ulcerative Colitis (UC), which was presented at the 2025 Crohn's and Colitis Congress [1][2]. Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [3]. - The company aims to transform the treatment landscape through a targeted approach with its therapeutics [3]. Product Development - The positive preclinical data for PALI-2108 is a significant milestone in Palisade's UC development program [2]. - The company has released a Virtual Investor segment discussing the implications of this data for its product development [2]. Investor Engagement - The Virtual Investor segment featuring Palisade Bio is available for viewing, along with additional videos from other Virtual Investor events [2].